Skip to main content
. 2018 Jun 11;18:37. doi: 10.1186/s12911-018-0606-x

Fig. 4.

Fig. 4

The dose-curves for the blocking of B7 ligands to CTLA-4 by ipilimumab (a) and tremelimumab (b) in the simulations performed in either of the B7 -knock-out model, where either of the B7 ligands and CD28 were removed. The complex formation of CTLA-4/B7–1 and CTLA-4/B7–2 in the absence of CD28 and antibody is also simulated (c)